Bio-Works secures new US customer for next-generation medicine development

Bio-Works Technologies AB has announced a new partnership with a major US biotechnology company for the development of a novel medicine. The contract is valued at SEK 2.8 million (approximately EUR 250,000).

The client, a global entity focused on innovative medicines and vaccines utilizing advanced mRNA technology, has selected Bio-Works to provide its products and expertise. The collaboration will specifically involve Bio-Works' solutions in the purification of biological medicines during the current development phase.

Bio-Works' technology is crucial for optimizing and streamlining the production process of biological drugs. Their solutions enable more efficient separation and purification of high-quality biological substances, which is vital for ensuring the safety and efficacy of new therapeutic treatments.

This agreement reinforces Bio-Works' standing within the biotechnology sector and its capacity to support the advancement of cutting-edge medical treatments. The company continues its investment in research and development to address global health challenges.